What is Affigen?
Affigen operates as a critical infrastructure provider for the global scientific research community, specializing in the discovery and development of high-quality antibodies. By bridging the gap between complex biological research and scalable laboratory solutions, the company has established itself as a key player in the life science supply chain. Their product portfolio, which includes recombinant proteins, ELISA kits, and advanced PCR quality control solutions, serves a diverse clientele spanning pharmacology, chemistry, and molecular biology. Through the integration of next-generation technologies, Affigen facilitates accelerated discovery cycles for labs worldwide, maintaining a robust market position as a reliable partner for academic and commercial research institutions.
How much funding has Affigen raised?
Affigen has raised a total of $17M across 1 funding round:
Series A
$17M
Series A (2017): $17M, investors not publicly disclosed
Key Investors in Affigen
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Affigen?
With this major enterprise-level funding, Affigen is poised to accelerate its research and development initiatives, focusing on the expansion of its proprietary antibody discovery platform. The strategic allocation of capital will likely prioritize the optimization of supply chain logistics and the scaling of production capabilities to meet the rising demand for high-fidelity research reagents. As the company transitions into its next phase of growth, stakeholders anticipate a broader integration of automated laboratory workflows and an increased footprint in emerging biotech markets. By leveraging this financial backing, Affigen aims to solidify its reputation as a cornerstone of modern scientific inquiry, ensuring that researchers have the necessary tools to push the boundaries of biological and chemical innovation.
See full Affigen company page
